[go: up one dir, main page]

PT2576782T - Arnsi e utilização dos mesmos em métodos e composições para o tratamento e/ou prevenção de condições oculares - Google Patents

Arnsi e utilização dos mesmos em métodos e composições para o tratamento e/ou prevenção de condições oculares

Info

Publication number
PT2576782T
PT2576782T PT11723600T PT11723600T PT2576782T PT 2576782 T PT2576782 T PT 2576782T PT 11723600 T PT11723600 T PT 11723600T PT 11723600 T PT11723600 T PT 11723600T PT 2576782 T PT2576782 T PT 2576782T
Authority
PT
Portugal
Prior art keywords
sirna
prevention
compositions
treatment
methods
Prior art date
Application number
PT11723600T
Other languages
English (en)
Inventor
Lopez-Fraga Marta
Isabel Jimenez Ana
Martinez Valcarel Tamara
Original Assignee
Sylentis Sau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sylentis Sau filed Critical Sylentis Sau
Publication of PT2576782T publication Critical patent/PT2576782T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/10Ophthalmic agents for accommodation disorders, e.g. myopia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3212'-O-R Modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PT11723600T 2010-05-27 2011-05-27 Arnsi e utilização dos mesmos em métodos e composições para o tratamento e/ou prevenção de condições oculares PT2576782T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10380074A EP2390327A1 (en) 2010-05-27 2010-05-27 siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions

Publications (1)

Publication Number Publication Date
PT2576782T true PT2576782T (pt) 2019-06-28

Family

ID=42829386

Family Applications (1)

Application Number Title Priority Date Filing Date
PT11723600T PT2576782T (pt) 2010-05-27 2011-05-27 Arnsi e utilização dos mesmos em métodos e composições para o tratamento e/ou prevenção de condições oculares

Country Status (20)

Country Link
US (1) US9018183B2 (pt)
EP (2) EP2390327A1 (pt)
JP (2) JP6008845B2 (pt)
KR (1) KR101585036B1 (pt)
CN (1) CN102918157B (pt)
AU (1) AU2011256978B2 (pt)
CA (1) CA2800412C (pt)
CY (1) CY1121787T1 (pt)
DK (1) DK2576782T3 (pt)
ES (1) ES2732351T3 (pt)
HR (1) HRP20191144T1 (pt)
HU (1) HUE044715T2 (pt)
LT (1) LT2576782T (pt)
MX (1) MX2012012501A (pt)
PL (1) PL2576782T3 (pt)
PT (1) PT2576782T (pt)
RS (1) RS58912B1 (pt)
SI (1) SI2576782T1 (pt)
TR (1) TR201909158T4 (pt)
WO (1) WO2011148193A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2726613B1 (en) 2011-06-30 2018-08-08 Arrowhead Pharmaceuticals, Inc. Compositions and methods for inhibiting gene expression of hepatitis b virus
GB201215857D0 (en) * 2012-09-05 2012-10-24 Sylentis Sau siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
JP2016516804A (ja) 2013-04-17 2016-06-09 ファイザー・インク 心血管疾患を治療するためのn−ピペリジン−3−イルベンズアミド誘導体
EP2865757A1 (en) 2013-10-22 2015-04-29 Sylentis, S.A.U. siRNA and their use in methods and compositions for inhibiting the expression of the PDK1 gene.
EP2865756A1 (en) 2013-10-22 2015-04-29 Sylentis, S.A.U. siRNA and their use in methods and compositions for inhibiting the expression of the FLAP gene.
EP3332007A4 (en) 2015-08-07 2019-07-17 Arrowhead Pharmaceuticals, Inc. RNAi Therapy Against Infection with Hepatitis B Virus
MA44908A (fr) * 2015-09-08 2018-07-18 Sylentis Sau Molécules d'arnsi et leur utilisation dans des procédés et des compositions pour inhiber l'expression du gène nrarp
JOP20170161A1 (ar) 2016-08-04 2019-01-30 Arrowhead Pharmaceuticals Inc عوامل RNAi للعدوى بفيروس التهاب الكبد ب
MX2021009702A (es) 2019-02-15 2021-09-14 Novartis Ag Metodos para tratar el dolor de la superficie ocular.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100872437B1 (ko) 2000-12-01 2008-12-05 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Rna 간섭을 매개하는 작은 rna 분자
CA2494930C (en) 2002-08-05 2021-03-09 Atugen Ag Modified forms of interfering rna molecules
DE10322662A1 (de) 2002-11-06 2004-10-07 Grünenthal GmbH Wirksame und stabile DNA-Enzyme
WO2006006948A2 (en) * 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
GB0521351D0 (en) * 2005-10-20 2005-11-30 Genomica Sau Modulation of TRPV expression levels
JP2010507387A (ja) 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド 新規のsiRNAおよびその使用方法
US20100292301A1 (en) 2007-02-28 2010-11-18 Elena Feinstein Novel sirna structures
WO2009023025A1 (en) * 2007-08-13 2009-02-19 Board Of Trustees Of Southern Illinois University Methods for treatment and prevention of ototoxicity by sirna
AU2008306455C1 (en) 2007-10-03 2014-04-17 Quark Pharmaceuticals, Inc. Novel siRNA structures

Also Published As

Publication number Publication date
KR101585036B1 (ko) 2016-01-13
LT2576782T (lt) 2019-07-10
TR201909158T4 (tr) 2019-07-22
CY1121787T1 (el) 2020-07-31
CN102918157A (zh) 2013-02-06
CA2800412C (en) 2019-09-17
EP2390327A1 (en) 2011-11-30
AU2011256978B2 (en) 2015-06-11
AU2011256978A1 (en) 2012-11-15
KR20130043121A (ko) 2013-04-29
CN102918157B (zh) 2016-06-29
US20130079389A1 (en) 2013-03-28
SI2576782T1 (sl) 2019-08-30
HRP20191144T1 (hr) 2019-10-04
DK2576782T3 (da) 2019-07-01
JP2013528382A (ja) 2013-07-11
RS58912B1 (sr) 2019-08-30
MX2012012501A (es) 2013-02-26
ES2732351T3 (es) 2019-11-22
CA2800412A1 (en) 2011-12-01
JP2016198104A (ja) 2016-12-01
WO2011148193A1 (en) 2011-12-01
JP6008845B2 (ja) 2016-10-19
EP2576782B1 (en) 2019-03-27
HUE044715T2 (hu) 2019-11-28
EP2576782A1 (en) 2013-04-10
US9018183B2 (en) 2015-04-28
PL2576782T3 (pl) 2019-09-30

Similar Documents

Publication Publication Date Title
HK1247821A1 (zh) 用於預防或治療眼科病症的方法和組合物
HK1198631A1 (en) Prevention and treatment of ocular conditions
PH12013500892A1 (en) Composition for use in the prevention and/or treatment of skin conditions and skin diseases
HUE044715T2 (hu) siRNS és felhasználása eljárásokban és kompozíciókban szembajok kezelésére és/vagy megelõzésére
HK1204988A1 (en) Methods and compositions for preventing or treating ophthalmic conditions
HK1258530A1 (zh) Serpina 1 sirnas:物質的組合物和治療方法
IL225793A0 (en) Methods and preparations for curing insulin-related medical conditions
PT2854910T (pt) Níveis de ceramida no tratamento e prevenção de infeções
HK1212377A1 (en) Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions sirna /
ZA201307058B (en) Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment
HK1211983A1 (en) Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions sirna /
IL222482A0 (en) Methods and compositions for the treatment of fluid accumulation in and/or under the retina
IL243237A0 (en) Methods and preparations for the treatment of fluid accumulation in and/or under the retina
PT2389936E (pt) Aminaftona para utilização no tratamento e/ou prevenção de enxaqueca